Safety and Efficacy of Therapeutic Hepatitis B Adenovirus Injection (T101) Combined With Nucleoside (Acid) Analogues in Chronic Hepatitis B Patients

NCT ID: NCT04189276

Last Updated: 2021-02-08

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-12-10
• Study Completion Date: 2021-12-31

Brief Summary

A multi-center, randomized, open-label, group controlled study to evaluate the safety and efficacy of T101 combined with nucleoside (acid) analogues in chronic hepatitis B patients.

Conditions

Hepatitis B Virus (HBV)

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Group1

T101+ETV(Entecavir) /TDF(Tenofovir)

Group Type: ACTIVE_COMPARATOR

ETV/TDF+T101 No.1

Intervention Type: BIOLOGICAL

Patients will be injected with T101 once on Day1 (Week0), Day8 (Week1), Day15 (Week2), Day106 (Week15), Day113 (Week16), Day120 (Week17), Day211 (Week30), Day218 (Week31), Day225 (Week32), Day316 (Week45), Day323 (Week46), Day330 (Week47); ETV or TDF will be administrated once each day successively until Day420.

Group2

T101+ETV/TDF

Group Type: ACTIVE_COMPARATOR

ETV/TDF+T101 No.2

Intervention Type: BIOLOGICAL

Patients will be injected with T101 once on Day1 (Week0), Day106 (Week15), Day211 (Week30), Day316 (Week45); ETV or TDF will be administrated once each day successively until Day420.

Group3

ETV or TDF

Group Type: ACTIVE_COMPARATOR

ETV or TDF

Intervention Type: BIOLOGICAL

Patients will be administrated ETV or TDF once each day successively until Day420.

Group4

Peg-IFNα-2b+ETV/TDF

Group Type: ACTIVE_COMPARATOR

ETV/TDF+Peg-IFNα-2b

Intervention Type: BIOLOGICAL

Patients will be administrated Peg-IFNα-2b successively once a week until Day330 (Week47); ETV or TDF will be administrated once each day successively until Day420.

Interventions

ETV/TDF+T101 No.1

Patients will be injected with T101 once on Day1 (Week0), Day8 (Week1), Day15 (Week2), Day106 (Week15), Day113 (Week16), Day120 (Week17), Day211 (Week30), Day218 (Week31), Day225 (Week32), Day316 (Week45), Day323 (Week46), Day330 (Week47); ETV or TDF will be administrated once each day successively until Day420.

Intervention Type: BIOLOGICAL

ETV/TDF+T101 No.2

Patients will be injected with T101 once on Day1 (Week0), Day106 (Week15), Day211 (Week30), Day316 (Week45); ETV or TDF will be administrated once each day successively until Day420.

Intervention Type: BIOLOGICAL

ETV or TDF

Patients will be administrated ETV or TDF once each day successively until Day420.

Intervention Type: BIOLOGICAL

ETV/TDF+Peg-IFNα-2b

Patients will be administrated Peg-IFNα-2b successively once a week until Day330 (Week47); ETV or TDF will be administrated once each day successively until Day420.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• 1. Patients between the ages of 18 and 60 years, male or female;
• 2. Body weight is no less than 45kg for female and no less than 50kg for male;
• 3. Meets the diagnosis and treatment standards of chronic hepatitis B in China's 2015 Guidelines for the Prevention and Treatment of Chronic Hepatitis B;
• 4. Currently, should have taken nucleoside (acid) analogues for 1 year or more;
• 5. HBV DNA<100 IU/ml; HBsAg is positive and no more than 3000 IU/ml；HBeAg is negative；
• 6. Be able to understand and sign informed consent.

Exclusion Criteria

Patients with any of the following items will not be enrolled in this study:

• 1. Pregnant or lactating women; male or female who have planned to have children from the start of the study to sixth month after the end of the study.
• 2. Have received interferon treatment within 6 months prior to the screening;
• 3. Have taken strong immunomodulators (such as adrenocortical hormone, thymosin alpha 1, thymosin 5, etc.) within 6 months before the screening, and the course of treatment was more than 2 weeks;
• 4. Have taken hepatotoxic drugs (such as dapsone, erythromycin, fluconazole, ketoconazole, rifampicin) within 6 months before screening, and the course of treatment was more than 2 weeks;
• 5. Currently or previously diagnosed or suspected with cirrhosis or liver cancer; or AFP > 50ng/ml;
• 6. Liver diseases caused by other causes: including alcoholic hepatitis, drug hepatitis, autoimmune liver disease;
• 7. Currently be infected of HAV, HCV, HDV, HEV, HIV and syphilis;
• 8. Have mental diseases, including but not limited to depression, anxiety, mania, schizophrenia;
• 9. Uncontrolled epilepsy;
• 10. Complicated with serious systemic diseases, including but not limited to: autoimmune diseases (such as psoriasis, systemic lupus erythematosus, etc.); not well controlled cardiovascular disease (such as high blood pressure, unstable angina pectoris, heart failure, etc.), endocrine system disease (such as thyroid function hyperfunction or loss, diabetes, etc.), respiratory system diseases (such as pulmonary infection, chronic obstructive pulmonary disease and pulmonary interstitial diseases, etc.), digestive system diseases (e.g., chronic colitis, etc.), kidney disease (such as chronic kidney disease, renal insufficiency, etc.), blood system diseases (such as autoimmune anemia, hemophilia, etc.); currently or previously diagnosed or suspected with malignant tumor;
• 11. Fundus diseases, such as not well controlled retinopathy, etc.;
• 12. Laboratory neutrophil count<1.5×109/L; platelet count <90×109/L;
• 13. Prothrombin time was extended by more than 3 seconds compared with the upper limit of normal reference value (ULN);
• 14. ALT>1.5×ULN; TBIL>2×ULN; SCR>1.5×ULN; serum creatine kinase >3×ULN; ALB<35g/L;
• 15. ANA>1:1000, anti-smooth muscle antibody>1:1000, thyrotropic hormone receptor antibody >2×ULN;
• 16. Allergic constitution or allergic to experimental drugs and excipients;
• 17. Plan to receive or have already had an organ transplant;
• 18. Participated in any clinical trial or taken any IMP (investigational medical product) within 3 months prior to the trial;
• 19. Other cases that could not be enrolled in the judgement of the investigators.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Tasly Tianjin Biopharmaceutical Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Beijing Youan Hospital,Capital Medical University

Beijing, Beijing Municipality, China

Beijing Ditan Hospital Capital Medical University

Beijing, Beijing Municipality, China

Tianjin Second People's Hospital

Tianjin, Tianjin Municipality, China

Countries

China

Other Identifiers

TSL-BM-T101-II

Identifier Type: -

Identifier Source: org_study_id